Status:
WITHDRAWN
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Metastatic Solid Tumors
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Patients with resistant metastatic solid tumors failing all conventional modalities who are eligible for immunotherapy by bispecific antibodies. First step: NST Second step: Patients with tumor cells...
Eligibility Criteria
Inclusion
- Patients with metastatic solid tumors expressing Her-2/Neu or EpCAM, with available match donor for NST.
- Patients with metastatic solid tumors not expected to be cured failing available conventional modalities, age \>18, with no upper age limit.
- Patients with metastatic breast cancer failing treatment with Herceptin.
- Patients with metastatic cancer cells expressing Her-2/Neu or EpCAM.
- Patients with evidence of disease following allogeneic stem cell transplantation with tumor cells expressing Her-2/Neu or EpCAM.
- Karnofsky performance status \>60%
- Life expectancy \> 3 months, to be able to assess response.
Exclusion
- Patients not fulfilling any of the above.
- Patients with active or ongoing infection that may endanger their life, whenever immunosuppression may be counter-indicated.
- Pregnant or lactating women.
- Patients positive for HIV.
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2005
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00149019
Start Date
May 1 2002
End Date
September 1 2005
Last Update
April 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120